Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today annou ...

Scientists have discovered novel drug candidates that could ultimately lead to new effective treatments for conditions caused ...

Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions ...

AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

Cobenfy (xanomeline tartrate and trospium chloride) was approved last year as a monotherapy for people with schizophrenia, in itself a large potential market, but the new study was hoping to ...

Positive top-line results from the Phase III EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of Cobenfy (xanomeline and trospium chloride) in ...